CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 140 enrolled
Drug / intervention
Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD) +1 moredrug
Likely dose
Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01678313
NCT01678313Phase 2Completed
CompareCT.gov

COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level

Buddhist Tzu Chi General Hospital·interventional·Posted Sep 5, 2012·Updated Jul 15, 2014

In Brief

A Phase 2 clinical trial evaluating Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD) and Doxazosin 4 mg every day (QD) for Benign Prostatic Hyperplasia. Completed, enrolled 140 participants across 1 site.

Detailed Summary

To investigate the therapeutic effect and safety of celecoxib adding on doxazosin and the potential predictive value of the absence of prostate cancer in the treatment of patients with LUTS/BPH and an elevated serum PSA level. Patients who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups for 3 months in 2:1 ratio as shown below: 1. Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD) 2. Doxazosin 4mg every day (QD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesTaiwan
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 5, 2012
Enrollment StartAug 1, 2012
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.8 years ago

Interventions

Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)drug

Study group

Doxazosin 4 mg every day (QD)drug

Control group